New hope for breast cancer: experimental combo targets hard-to-treat tumors
Disease control
Not yet recruiting
This early-phase study tests a new drug called HRS-6209 combined with standard hormone therapies (fulvestrant or letrozole) in people with a specific type of advanced breast cancer (HR-positive, HER2-negative). The main goals are to check safety and how the drug moves through the…
Phase: PHASE1 • Sponsor: Atridia Pty Ltd. • Aim: Disease control
Last updated May 14, 2026 12:02 UTC